HopeStage
Back to all studies
CompletedNCT00401089

Panax ginseng added to antipsychotic treatment for schizophrenia

About this titleRead the official source — NCT00401089
Medication studyAges 18–65Canada + United Kingdom
The study in practice

Understand this study

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations
Kingston and 3 more locationsSee all locations and recruitment
Study phase
Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateDecember 2002
Recruitment status
Completed
Enrollment listed in the registry
60
Sponsor
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Sponsor type
Research institute
Study type
Drug
Intervention type
Drug
Study phase
Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
Locations
Canada, United Kingdom
Age range
From 18 Years to 65 Years
Official registry ID
NCT00401089
Official title
Show the full official title

A Placebo-controlled Cross Study of Panax Ginseng in Augmentation of Antipsychotics in 60 Partially Treatment Responsive Patients With Schizophrenia

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Kingston, Canada · St. Thomas, Canada · Thunder Bay, Canada

1 more locations
  • Harrow, United Kingdom

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's, a research institute.

Did this study involve medication?

Yes. The study involved medication, including Panax Ginseng.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies